Metagenomi Therapeutics, Inc. Income Statement
MGX|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Metagenomi Therapeutics, Inc. reported $25M in revenue and $88M in net loss for FY2025. Revenue decreased 43.7% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.90 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $25.2M | $44.8M |
| SG&A Expense | $26.8M | $28.8M |
| R&D Expense | $94.4M | $94.4M |
| Operating Income | -$96.0M | -$78.5M |
| Income Tax | -$58.0K | $8.0M |
| Net Income | -$87.9M | -$68.3M |
| EPS (Basic) | -$2.36 | -$20.05 |
| EPS (Diluted) | -$2.36 | -$20.05 |
| Shares Outstanding | 37.4M | 3.4M |
| Operating Margin | -380.9% | -175.4% |
| Profit Margin | -348.5% | -152.5% |